Internal Medicine, Hematology & Oncology · Baton Rouge, LA
NPI
1144458704
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
4950 Essen Ln Ste 500
Baton Rouge, LA, 70809
Phone (225) 767-0847
Groups this clinician bills Medicare through
Medicare paid, 2024
$84K
1,260 services
Medicare patients, 2024
264
Average age 71
Drug cost, 2024
$13.3M
2,821 prescriptions
Company payments, 2025
$36K
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Andrew P Dalovisio was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 202 times for 109 patients. In total Andrew P Dalovisio billed 1,260 services in 20 codes, and Medicare paid $84K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-05-08.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 202 | 109 | $12.57 | $2,539 |
| 99214 Office E&M - Established | Facility | 190 | 108 | $67.51 | $13K |
| 99215 Office E&M - Established | Facility | 190 | 85 | $100.33 | $19K |
| 99233 Hospital E&M - Subsequent | Facility | 186 | 35 | $88.74 | $17K |
| 99214 Office E&M - Established | Office | 117 | 67 | $85.09 | $9,955 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 102 | 59 | $12.54 | $1,279 |
| 99215 Office E&M - Established | Office | 100 | 50 | $122.25 | $12K |
| 99441 Telephone Services | Office | 29 | 20 | $41.48 | $1,203 |
| 99238 Hospital Discharge Management | Facility | 19 | 17 | $61.82 | $1,175 |
| 99205 Office E&M - New | Facility | 14 | 14 | $127.63 | $1,787 |
| 99223 Hospital E&M - Initial | Facility | 13 | 12 | $132.36 | $1,721 |
By year: 2022 $54K for 641 services; 2023 $65K for 765 services; 2024 $84K for 1,260 services.
Medicare prescription drug claims, 2024
In 2024, the drug Andrew P Dalovisio prescribed most often to Medicare patients was Acyclovir, with 325 prescriptions and refills. In total Andrew P Dalovisio wrote 2,821 Medicare prescriptions that cost $13.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 325 | 530 | 81 | $5,034 |
| Lenalidomide Generic | 314 | 314 | 60 | $4.6M |
| Revlimid Lenalidomide | 156 | 156 | 38 | $3.0M |
| Pomalyst Pomalidomide | 104 | 104 | 20 | $2.4M |
| Oxycodone Hcl Generic | 102 | 102 | 24 | $3,108 |
| Gabapentin Generic | 94 | 122 | 25 | $1,137 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 80 | 80 | 17 | $2,143 |
| Dexamethasone Generic | 79 | 144 | 39 | $2,203 |
| Eliquis Apixaban | 48 | 63 | 11 | $35K |
| Alprazolam Generic | 48 | 48 | Under 11 | $140 |
| Morphine Sulfate Er Morphine Sulfate | 46 | 46 | Under 11 | $1,610 |
| Ondansetron Odt Ondansetron | 46 | 51 | 20 | $1,089 |
| Pantoprazole Sodium Generic | 45 | 87 | 13 | $373 |
| Amlodipine Besylate Generic | 44 | 62 | Under 11 | $203 |
| Hydroxyurea Generic | 41 | 100 | 15 | $1,208 |
Brand drugs: - claims; generic drugs: 2,224 claims; opioid claims: 345.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Andrew P Dalovisio $36K ($36K in general payments such as food, travel and fees) from 29 companies. The largest payer was Janssen Biotech, Inc. with $18K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 19 | $18K |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $9,675 |
| Genmab U.S., Inc. GMAB | 9 | $6,024 |
| Karyopharm Therapeutics Inc. KPTI | 3 | $642 |
| Daiichi Sankyo Inc. 4568.T | 8 | $256 |
| Adaptive Biotechnologies Corporation ADPT | 4 | $192 |
| Pfizer Inc. PFE | 2 | $182 |
| Abbvie Inc. ABBV | 5 | $106 |
| GlaxoSmithKline, LLC. GSK | 5 | $103 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $84.58 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.